Last reviewed · How we verify
NCT04815018: COVID-19
Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2
trial in SARS-CoV-2 Infection in 185 participants. Terminated before completion.
30 May 2021
Quick facts
| Lead sponsor | Pathnostics |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 185 |
| Start date | 7 October 2020 |
| Primary completion | 30 May 2021 |
| Estimated completion | 30 May 2021 |
| Sites | 4 locations across United States |
Conditions studied
- SARS-CoV-2 Infection — all drugs for SARS-CoV-2 Infection →
- Bacterial Respiratory Tract Infection — all drugs for Bacterial Respiratory Tract Infection →
- Viral Respiratory Tract Infection — all drugs for Viral Respiratory Tract Infection →
Sponsor
Pathnostics
Who can join
60 and older, any sex, with SARS-CoV-2 Infection or Bacterial Respiratory Tract Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a longitudinal, prospective observational study focusing on health-related outcomes relative to potential changes in the respiratory microbiome seen with weekly SARS-CoV-2 testing in nursing home residents.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04815018
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for SARS-CoV-2 Infection
Currently open trials in the same condition.
- NCT07079670 — Safety and Immunogenicity of NVX-CoV2705 · Phase 3 · active not recruiting
- NCT05697068 — Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos · NA · active not recruiting
- NCT05172011 — Understanding the Long-term Impact of COVID on Children and Families · active not recruiting
- NCT05141058 — T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients · Phase 1 · recruiting
- NCT05046470 — SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonia - Brussels: An Epidemiological Pilot Study · active not recruiting
Other Pathnostics trials
Trials by the same sponsor.
- NCT05385536 — Evaluating UTI Outcomes in at Risk Populations · completed
- NCT05091931 — Diagnosis, Antibiotic Prescribing Practices and Outcomes of cUTI in an Outpatient Setting · completed
- NCT04815369 — Evaluating UTI Diagnosis in Nursing Homes · withdrawn
- NCT04817865 — Comparison of Pre-procedural PCR and Culture-based UTI Assessment Prior to Intravesical Botox Injection · withdrawn
- NCT03931538 — Rapid Molecular Organism Identification and Mixed Flora Antibiotic Resistance Profiling (MixAR) Prospective Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04815018 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pathnostics
- Last refreshed: 30 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04815018.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing